This is a summary of the presentation by prof. Stephan Jacob, in which he talked about the management of diabetes, focusing on the shift from glucose to CV risk management in patients with diabetes.
A posthoc analysis of the LEADER trial showed that liraglutide showed more pronounced CV benefits in T2DM patients aged 75 years or older, than in those between 60 and 74 years of age.
CME accredited course focussed on how new developments with antidiabetic drugs will impact the management of CVD. Member registration (free) is needed to enroll in this course
Different GLP-1RAs have shown different effects in CV outcomes trials. Prof Rydén scrutinizes the results of the trials to learn more about the effects of individual GLP-1RAs and what the differences may originate from.
After considering the incretin effect and how this is impaired in T2DM, prof. Knop sets out how the various effects of GLP-1 receptor agonists can help in management of T2DM.
In a phase 2b randomized trial, LY3298176, a dual GIP and GLP-1 RA, led to a statistically significant and clinically meaningful dose-dependent improvement of glucose lowering and body weight reduction compared with dulaglutide.
The phase 3a PIONEER 6 trial met its primary endpoint, showing non-inferiority with regard to MACE, which was driven by a significant reduction in CV and all-cause mortality, compared to placebo, on top of standard care in T2DM.
The REWIND study met its primary efficacy endpoint, showing that administration of the GLP-1 RA dulaglutide once-weekly significantly reduces MACE versus placebo in adult diabetic patients with or without CVD.
This umbrella review of recent systematic reviews and meta-analyses compared the effectiveness and underlying mechanisms of various prevention and treatment strategies to regulate blood glucose.
In recent years, new insights into the CV risk associated with diabetes have resulted in a new management approach of T2DM. Prof. Deanfield explains the rationale of a multifactorial approach.
In a posthoc analysis of the LEADER trial, liraglutide treatment was associated with fewer CV outcomes patients with type 2 diabetes and chronic kidney disease at high CV risk.
CME accredited course focussed on the role of GLP-1 receptor agonists in preventing cardiovascular disease in patients with T2DM. Member registration (free) is needed to enroll in this course